These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 29460902)

  • 1. [The efficacy of cortexin and memantinol (memantine) in the treatment of cognitive impairment in patients with chronic cerebral ischemia].
    Fedin AI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(1):30-36. PubMed ID: 29460902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cognitive impairment in patients poluchennym ischemic stroke in the acute and early recovery periods in the process of neuroprotection low-dose drug cortexin].
    Belova LA; Mashin VV; Abramova VV; Proshin AN; Ovsjannikova AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(8 Pt 2):40-43. PubMed ID: 27905386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dose-dependent effects of cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled study)].
    Fedin AI; Belskaya GN; Kurushina OV; Kovalchuk VV; Starych EV; Chichanovskaya LV; Baranova OA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(9):35-42. PubMed ID: 30335070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Akatinol memantine in patients with vascular cognitive disorders].
    Gudkova AA; Sorokina IB; Iakovlev AA; Guliaeva NV; Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):37-40. PubMed ID: 21311485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A multicenter observation study of the efficacy of cortexin and recognan (citicoline) in the treatment of cognitive impairments in chronic cerebrovascular pathology].
    Belova LA; Mashin VV; Dudikov EM; Belov DV; Krupennikov AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2):35-38. PubMed ID: 30874524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Results of a multicenter study on the efficacy of cortexin in treatment of cognitive dysfunction in children].
    Zykov VP; Serebrennikova EB; Panchenko TN; Sycheva YB; Presnyakova SN; Mazur EL; Salova MN; Golubeva ES; Khromova SK
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(3):27-31. PubMed ID: 29652302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
    Peyro Saint Paul L; Creveuil C; Heinzlef O; De Seze J; Vermersch P; Castelnovo G; Cabre P; Debouverie M; Brochet B; Dupuy B; Lebiez P; Sartori É; Clavelou P; Brassat D; Lebrun-Frenay C; Daplaud D; Pelletier J; Coman I; Hautecoeur P; Tourbah A; Defer G
    J Neurol Sci; 2016 Apr; 363():69-76. PubMed ID: 27000224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Possibilities of pharmacological modulation of brain glutamatergic system in the treatment of vascular cognitive impairment].
    Litvinenko IV; Vorob'ev SV; Lobzin VY; Lupanov IA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(9):29-35. PubMed ID: 24107877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Multicenter observational program for evaluation of the effectiveness of the recognan (citicoline) in the correction of cognitive impairment in patients with chronic cerebrovascular pathology].
    Mashin VV; Belova LA; Bakhtogarimov IR; Bergelson TM; Sharafutdinova RR
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(8):39-43. PubMed ID: 28884715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI).
    Ferris S; Schneider L; Farmer M; Kay G; Crook T
    Int J Geriatr Psychiatry; 2007 May; 22(5):448-55. PubMed ID: 17117395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [An open clinical trial of cortexin in treatment of brain ischemia].
    Mashin VV; Belova LA; Chaplanova OI; Khusnullina AF; Manasian AM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(9):49-52. PubMed ID: 25403301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study.
    Schifitto G; Navia BA; Yiannoutsos CT; Marra CM; Chang L; Ernst T; Jarvik JG; Miller EN; Singer EJ; Ellis RJ; Kolson DL; Simpson D; Nath A; Berger J; Shriver SL; Millar LL; Colquhoun D; Lenkinski R; Gonzalez RG; Lipton SA; ; ;
    AIDS; 2007 Sep; 21(14):1877-86. PubMed ID: 17721095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
    Bullock R
    Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of 12-week open-label memantine treatment on cognitive function improvement in patients with alcohol-related dementia.
    Cheon Y; Park J; Joe KH; Kim DJ
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):971-83. PubMed ID: 18346293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative study of protective effects of Cortexin, Cerebrolysin and Actovegin on memory impairment, cerebral circulation and morphological changes in the hippocampus of rats with chronic brain ischemia].
    Tyurenkov IN; Kurkin DV; Kalatanova AV; Dorotenko AR; Bakulin DA; Morkovin EI; Verholyak DV; Gorbunova YV; Atapina NV; Smirnov AV; Schmidt MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(8):83-89. PubMed ID: 32929929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, placebo-controlled study of memantine in the treatment of major depression.
    Zarate CA; Singh JB; Quiroz JA; De Jesus G; Denicoff KK; Luckenbaugh DA; Manji HK; Charney DS
    Am J Psychiatry; 2006 Jan; 163(1):153-5. PubMed ID: 16390905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Memantine and catatonic schizophrenia.
    Thomas C; Carroll BT; Maley RT; Jayanti K; Koduri A
    Am J Psychiatry; 2005 Mar; 162(3):626. PubMed ID: 15741490
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of Cognitive Impairment and the Role of Demographic Factors in Disease Progression: The Final Results of the Russian Observational Program "DIAMANT".
    Parfenov VA; Zhivolupov SA; Poverennova IE; Nesterova MV; Ushakova SE; Zhukova NG; Glazunov AB; Nikulina KV; Alexandrov MV; Lapatukhin VG; Zhestikova MG
    Eur Neurol; 2020; 83(6):591-601. PubMed ID: 33202402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memantine therapy for Alzheimer disease in real-world practice: an observational study in a large representative sample of French patients.
    Vidal JS; Lacombe JM; Dartigues JF; Pasquier F; Robert P; Tzourio C; Alpérovitch A
    Alzheimer Dis Assoc Disord; 2008; 22(2):125-30. PubMed ID: 18525283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
    Feusner JD; Kerwin L; Saxena S; Bystritsky A
    Psychopharmacol Bull; 2009; 42(1):81-93. PubMed ID: 19204653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.